Institutional members access full text with Ovid®

Share this article on:

Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder

Sapre, Nikhil; Herle, Praduymna; Anderson, Paul D.; Corcoran, Niall M.; Hovens, Christopher M.

doi: 10.1097/PAT.0000000000000110

Summary: Molecular biomarkers are used routinely in the clinical management of several tumours such as prostate, colon, ovarian and pancreatic cancer but management decisions in bladder cancer remain dependent on clinical and pathological criteria, which are limited in their ability to predict outcomes. Molecular markers are urgently needed in detection, surveillance and prognostication of bladder cancer as well as to predict treatment response to intravesical and systemic therapies. Advances in cancer genomics and platforms for biomarker profiling have led to a plethora of biomarkers, which must now be rigorously validated in the clinical setting. Pre-clinical and clinical studies exploring the role of emerging targeted therapies to risk stratify and reduce cancer progression are also needed.

Department of Urology, Royal Melbourne Hospital, and Department of Surgery, University of Melbourne, Parkville, Vic, Australia

Address for correspondence: Dr N. Sapre, Department of Surgery, Level 5 Clinical Sciences Building, Royal Melbourne Hospital, Grattan Street, Parkville, Vic 3050, Australia. E-mail:

Received 25 September, 2013

Revised 21 December, 2013

Accepted 1 January, 2014

© 2014 Royal College of Pathologists of Australasia
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website